For OMA distribution only. Trademarks may be registered and are the property of their respective owners. © 2014 Medtronic, Inc. All rights reserved. 10129897DOC_1A.

Slides:

Advertisements

Similar presentations

Trademarks may be registered and are the property of their respective owners. Today’s discussion may regard information or indications not evaluated by.

Advertisements

STENT THROMBOSIS: WHICH IMPACT IN REAL CLINICAL PRACTICE? Giuseppe Biondi Zoccai Divisione di Cardiologia, Università di Torino Ospedale S. Giovanni Battista.

Five-Year Follow-up of Safety and Efficacy of the Resolute Zotarolimus-Eluting Stent: Insights from the RESOLUTE Global Clinical Trial Program in Approximately.

Optimal Stent Expansion and Optimization

Bioabsorbable stents: early clinical results Dr Angela Hoye MB ChB, PhD Senior Lecturer in Cardiology Hull & East Yorkshire Hospitals.

3rd CEEGI Advisory Board1 Resolute in the DES era: Indications & Limitations Georgios I. Papaioannou, MD, MPH, FACC, FSCAI Athens Medical Center Cardiac.

Resolute all comers trial Objective:To compare the efficacy and safety of the new generation ZES stent versus the everolimus eluting stent. Study:Multicenter,

ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs. Everolimus-Eluting Stents for Treatment of Unprotected Left Main Coronary Artery Lesions Julinda Mehilli,

2 Year Clinical Outcomes from the Pivotal RESOLUTE US Study Laura Mauri MD, MSc on behalf of the RESOLUTE US Investigators Brigham and Women’s Hospital.

For distribution in the USA only. Trademarks may be registered and are the property of their respective owners. © 2013 Medtronic, Inc. All rights reserved.

Resolute IntegrityTM Zotarolimus-Eluting Stent System

CURRENT PUBLICATION TRENDS IN INTERVENTIONAL CARDIOLOGY Giuseppe Biondi Zoccai Division of Cardiology, University of Turin, Turin, Italy.

© 2012 EuroIntervention. All rights reserved. EuroIntervention 2012;8: Comparison of intravascular ultrasound versus angiography-guided drug-eluting.

The Stent of Choice in ACS patients The Stent of Choice in ACS 1) The Rationale…

BURZOTTA F. 1, PAN M. 2 (CO-FIRST AUTHOR), TRANI C. 1, MEDINA A. 3, SUÀREZ DE LEZO J. 2, NICCOLI G. 1, ROMERO M. 2, PORTO I. 1, MAZUELOS F. 2, LEONE A.M.

RITA-3 Is this a benign lesion in a benign condition? Who Needs Angioplasty in 2008? Stable Angina Stable Angina Keith A A Fox Professor of Cardiology.

Giuseppe Biondi Zoccai Division of Cardiology University of Turin, Turin Critical aspects of trials on the new generation DES 31st.

Not for distribution in the U.S. Trademarks may be registered and are the property of their respective owners. © 2012 Medtronic, Inc. All rights reserved.

1 of Presented by Gregg W. Stone, MD, ACC PROMUS Stent is a private-labeled Xience V Everolimus Eluting Coronary Stent System manufactured.

For OMA distribution only. Trademarks may be registered and are the property of their respective owners © 2015 Medtronic, Inc. All Rights Reserved DOC_1A.

Upendra Kaul, MD for the TUXEDO INDIA Investigators Paclitaxel Eluting Versus Everolimus Eluting Stents in Patients with Diabetes Mellitus and Coronary.

Upendra Kaul, MD for the TUXEDO INDIA Investigators Paclitaxel Eluting Versus Everolimus Eluting Stents in Patients with Diabetes Mellitus and Coronary.

LM strategy Interventional cardiology dpt Cardiovascular Hospital - Lyon - France Gilles Rioufol MD PhD INSERM U1060 High Tech Marseille, 26 Janvier 2012.

RESOLUTE US One-Year Clinical Outcomes from the Pivotal Multicenter RESOLUTE US Study Objective To evaluate the clinical effectiveness of the Resolute.

Harmonizing Outcomes with RevascularIZatiON and Stents (HORIZONS) Trial HORIZONS Trial.

Un update clinico in tema di BVS Bernardo Cortese Intv’ Cardiology, A.O. Fatebenefratelli bernardocortese.com Bernardo Cortese MD FESC.

For OMA distribution only. Trademarks may be registered and are the property of their respective owners. © 2013 Medtronic, Inc. All rights reserved. UC ML.

Bayesian approach to equivalence study of medical device 1 1.

Clinical Experience with the Bio Active Stent (BAS) in FINLAND 9 e CFCI Hotel Meridien Etoile Paris, France 10 Octobre 2007 Pasi Karjalainen, MD, PhD.

Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki.

For OMA distribution only. © 2014 Medtronic, Inc. All rights reserved DOC_1A 03/14 Four-Year Outcomes Following Resolute Zotarolimus-Eluting Stent.

Information contained herein for presentation outside of the U.S. and Japan only. Not to be reproduced, distributed or excerpted. AP Rev. A 1 Abbott.

Is there any role for intravascular ultrasound in bifurcation lesions? Giuseppe Biondi-Zoccai, MD University of Turin, Turin, Italy.

Drug-Eluting Stents in Challenging Lesions: Randomized Trials and Registries.

Cardioprotective Effects of Postconditioning in Patients Treated with Primary PCI Evaluated with Magnetic Resonance Jacob T Lønborg Niels Vejlstrup, Erik.

The REVA Tyrosine-Derived Polycarbonate Bioresorbable Scaffold: Long-term Outcomes Using Multimodality Imaging Greg L. Kaluza, MD, PhD, FACC Director of.

©2012 Abbott. All rights reserved. AP Rev. A Information contained herein for use with physicians outside the US and Japan only. Absorb is authorized.

Date of download: 7/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Clinical restenosis after coronary stenting: perspectives.

Date of download: 7/6/2016 Copyright © The American College of Cardiology. All rights reserved. From: Long-Term Clinical Results Following Stenting of.

For OMA distribution only. Trademarks may be registered and are the property of their respective owners. © 2012 Medtronic, Inc. All rights reserved DOC_1A.

Durable Polymer DES: 5 Year Outcomes RESOLUTE Update Sigmund Silber, MD FESC, FACC, FAHA Heart Center at the Isar Munich, Germany On Behalf of the RESOLUTE.

Prof. Dr. Sigmund Silber, FESC, FACC On behalf of the RESOLUTE

Global Experience with Peripheral DCBs/Stent Studies: C.R. Bard

David E. Kandzari, MD on behalf of the BIONICS investigators

Everolimus-eluting Bioresorbable Vascular Scaffolds in Patients with Coronary Artery Disease: ABSORB III Trial 2-Year Results Stephen G. Ellis, MD,

Evaluation of XIENCE V Everolimus-Eluting and Taxus Express2 Paclitaxel-Eluting Coronary Stents in Patients With Jailed Side Branches From the SPIRIT.

12 Month Outcomes in Patients with Diabetes Mellitus Implanted with a Resolute Zotarolimus-eluting Stent: Initial Results from the RESOLUTE Global Clinical.

ABSORB Japan: 3-year Clinical and Angiographic Results of a Randomized trial Evaluating the Absorb Bioresorbable Vascular Scaffold vs. Metallic Drug-eluting.

BRS Summit – Scaffold Fractures

Debate: What Does the Future Hold for the Treatment of Unprotected Left Main Disease? More PCI No More Routine Surgery Ron Waksman, MD, FACC Washington.

DES Should be Used as the Default Stent in ACS!

The RESOLUTE Program: today and tomorrow

On behalf of J. Belardi, M. Leon, L. Mauri,

Second Generation DES Associated with Less Late and Very Late Stent Thrombosis Compared to First Generation DES Donald E. Cutlip, MD Beth Israel Deaconess.

Stenting of Coronary Arteries in Non Stress/Benestent Disease

(p < for group 1 or 2 vs. group 3)

DANISH Trial design: Patients with nonischemic cardiomyopathy were randomized to ICD implantation (n = 556) versus usual care (n = 560). Results (p = 0.28)

Primary endpoint at 1 year

EXCEL Trial design: Patients with unprotected left main disease were randomized to either PCI with an Xience everolimus-eluting stent (EES) or CABG. They.

SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.

TUXEDO–India Trial design: Patients with type 2 diabetes mellitus (DM2) and coronary artery disease undergoing PCI were randomized to receive Taxus Element.

Dean J. Kereiakes et al. JACC 2017;70:

3-Year Clinical Outcomes From the RESOLUTE US Study

(p = 0.32 for noninferiority)

FOR DISTRIBUTION BY MEDTRONIC OFFICE OF MEDICAL AFFAIRS ONLY.

CHAMPION Trial design: Patients with recent hospitalization for heart failure were implanted with a pulmonary artery pressure monitor and randomized so.

SMART-STRATEGY Trial design: Patients with a bifurcation coronary lesion were randomized to a conservative strategy (n = 128) vs. an aggressive strategy.

Effects of Pay-for-Performance on the Quality of Primary Care in England Mean Scores for Clinical Quality at the Practice Level for Aspects of Care for.

Comparison of Everolimus-Eluting and Paclitaxel-Eluting Stents: First Report of the Five-Year Clinical Outcomes from.

Primary safety endpoint

Presentation transcript:

For OMA distribution only. Trademarks may be registered and are the property of their respective owners. © 2014 Medtronic, Inc. All rights reserved DOC_1A 03/2014 Bioabsorbable Stents (BAS) & Drug-Eluting Stents (DES) Angina Status & TLF Creep

For OMA distribution only. Trademarks may be registered and are the property of their respective owners. © 2014 Medtronic, Inc. All rights reserved DOC_1A 03/2014 Hypothesis: Can BVS Implantation Reduce Angina? Are ABSORB angina rates lower than 2 nd generation DES? Stone TCT 2013

For OMA distribution only. Trademarks may be registered and are the property of their respective owners. © 2014 Medtronic, Inc. All rights reserved DOC_1A 03/2014 Variation of Angina Rates from Recent 2 nd Gen DES Trials There is a wide variation in angina status from 10.5% to 28% at 1 YearThere is a wide variation in angina status from 10.5% to 28% at 1 Year On-label patient data from the RESOLUTE Trials were analyzed based on reported angina status between follow up intervals. Xience and ABSORB data presented at TCT Event rates are expressed as KM estimates. Change in Angina Status may not be product specific Variation in Angina Status 10.5% 18.0% % 28.1% 2 Yeung AC, et al. JACC. 2011;57: Serruys PW, et al. N Engl J Med. 2010;363:

For OMA distribution only. Trademarks may be registered and are the property of their respective owners. © 2014 Medtronic, Inc. All rights reserved DOC_1A 03/2014 Does an increase in TLF over time always occur in 2 nd Gen DES? Is TLF Creep a real phenomenon with all DES studies? Stone TCT 2013

For OMA distribution only. Trademarks may be registered and are the property of their respective owners. © 2014 Medtronic, Inc. All rights reserved DOC_1A 03/2014 Careful vessel preparation can influence TLF The RESOLUTE Japan Trial was conducted using careful lesion preparation and extensive imaging.The RESOLUTE Japan Trial was conducted using careful lesion preparation and extensive imaging. Months Number at risk Target Lesion Failure (%) 4.0% The 3-year TLF rate from RESOLUTE Japan was 4.0%The 3-year TLF rate from RESOLUTE Japan was 4.0% No TLF creep was seen in the RESOLUTE Japan trialNo TLF creep was seen in the RESOLUTE Japan trial RESOLUTE Japan Lesion Prep/Imaging IVUS Use (%)99 Pre-Dilation Pressure Range (min, max) 6.00, Post-Dilatation (%)78 RESOLUTE Japan TLF to 3 Yrs

For OMA distribution only. Trademarks may be registered and are the property of their respective owners. © 2014 Medtronic, Inc. All rights reserved DOC_1A 03/2014 Insights on angina status and TLF creep from recent 2 nd generation DES trials Angina status may not be product specific as varying low angina rates have been shown by recent 2 nd generation DES trials.Angina status may not be product specific as varying low angina rates have been shown by recent 2 nd generation DES trials. TLF creep can be influenced and reduced in 2 nd generation DES trials with enhanced vessel/lesion prep and use of imaging as seen with the RESOLUTE Japan clinical trial.TLF creep can be influenced and reduced in 2 nd generation DES trials with enhanced vessel/lesion prep and use of imaging as seen with the RESOLUTE Japan clinical trial.